Business Context and Reporting Period
Seer, Inc. (Nasdaq: SEER) is a life sciences company commercializing the Proteograph Product Suite for proteomic analysis. This Form 8-K, dated August 12, 2021, reports financial results for the quarter ended June 30, 2021. The company is classified as an emerging growth company.
Key Financial Metrics
| Metric | Q2 2021 | Q2 2020 |
|---|---|---|
| Total Revenue | $1.33 million | $0.07 million |
| Gross Profit | $0.75 million | $0.07 million |
| Gross Margin | 56% | 100% |
| Operating Expenses | $17.42 million | $6.44 million |
| Net Loss | $16.62 million | $6.12 million |
| Cash, Cash Equivalents, and Investments | $517.77 million | Filing text does not provide a clear comparative value for Q2 2020 |
| Net Loss Per Share (Basic & Diluted) | $(0.27) | $(0.63) |
Revenue breakdown for Q2 2021 included $0.84 million in product revenue, $0.38 million in related party revenue, and $0.12 million in grant revenue.
Material Changes Versus Prior Period
- Revenue Growth: Revenue increased significantly from $71,000 in Q2 2020 to $1.33 million in Q2 2021, driven by the commencement of sales for the Proteograph Product Suite and services for PrognomIQ.
- Expense Increase: Operating expenses rose from $6.4 million to $17.4 million, primarily due to increased personnel costs, stock-based compensation, and expenses associated with becoming a publicly traded company.
- Net Loss Expansion: Net loss widened from $6.1 million to $16.6 million, reflecting the substantial increase in operating expenses despite revenue growth.
- Liquidity: As of June 30, 2021, total cash, cash equivalents, and investments were approximately $518 million.
Outlook, Commentary, and Risks
Management highlighted the shipment and installation of the Proteograph Product Suite to additional sites, including the first international customer, and the booking of initial revenue. The company is on track to achieve a high single-digit number of Limited Release customers in 2021. A new distribution partnership with Enlight Medical was announced to accelerate entry into the Chinese market.
Forward-looking statements in the filing caution that actual results may differ due to risks regarding the timing and ability to enable unbiased, deep, and rapid proteomics at scale, the number of Limited Release customers achieved, and plans for the China market.
Investor Verification Checklist
- Verify the sustainability of the 56% gross margin as product sales scale.
- Confirm the timeline for achieving the projected "high single digit" number of Limited Release customers in 2021.
- Assess the impact of the new distribution partnership with Enlight Medical on future revenue growth in China.
- Monitor the burn rate given the $17.4 million quarterly operating expense level against the $518 million cash position.
- Review the upcoming Form 10-Q for detailed risk factors and segment reporting.